Pfizer CEO Albert Bourla (L) and Moderna CEO Stéphane Bancel (Matthew Busch/Bloomberg via Getty Images; Nancy Lane/The Boston Herald via AP Images, Pool)
March 17, 2023 10:47 AM EDTUpdated 11:14 AM
People
Pharma

Pfiz­er's Bourla and Mod­er­na's Ban­cel saw com­pen­sa­tion bumps in 2022

Kyle LaHucik

Senior Reporter

More Big Phar­mas and hot­ly-watched biotechs have dis­closed the to­tal com­pen­sa­tion fig­ures for their ex­ec­u­tives, high­light­ing the pay pack­ages of Covid-19 be­he­moths, in­sulin mak­ers and rare dis­ease drug de­vel­op­ers.

Pfiz­er CEO Al­bert Bourla brought in $33.01 mil­lion, Mod­er­na’s Stéphane Ban­cel racked up $19.36 mil­lion, Eli Lil­ly’s Dave Ricks lined up $21.398 mil­lion, Sanofi’s Paul Hud­son snagged €10.718 mil­lion (about $11.38 mil­lion), John­son & John­son’s Joaquin Du­a­to made $13.09 mil­lion, and the leader of Hori­zon Ther­a­peu­tics, Tim Wal­bert, nabbed $20.1 mil­lion last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is ready to elim­i­nate the in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

Re­gen­eron en­ters ven­ture in­vest­ing with $500M, poach­es se­nior part­ner from ARCH

ADC deal­mak­ing is red hot. Is it sus­tain­able?

Fed­er­al judge grants pause to Pfiz­er, BioN­Tech in Covid-19 patent law­suit tri­al brought by Mod­er­na

New FDA tri­al in­no­va­tion cen­ter launch­es with demon­stra­tion to in­crease in­dus­try in­ter­ac­tions

A service from the Financial Times